SynthesisWorld journal of urology2025
The suggested dosage and course of thiazide diuretics on preventing recurrent urolithiasis: an upstate meta-analysis.
Synthesis in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From mechanisms to clinical practice: a review of diuretic therapy in pediatric nephrology.Pediatric nephrology (Berlin, Germany) · 2026Review
- Ten tips on the work-up and management of CKD patients with nephrolithiasis.Clinical kidney journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOver the past few decades, many studies assessing the effect of thiazide diuretics showed controversial results. Additionally, recent guidelines fail to address the optimal dosage and treatment duration of thiazide diuretics. Therefore, we conducted a meta-analysis to evaluate the efficacy, optimal dosage, and treatment duration of thiazide diuretics in preventing recurrent urolithiasis.
methodsWe conducted a comprehensive search of three electronic databases (PubMed, Embase and Cochrane Library) up to January 2024, utilizing specific keywords to identify eligible studies. Subsequently, we performed an overall meta-analysis. Subgroup analysis was also performed to evaluate the efficacy, optimal dosage, and treatment duration of thiazide diuretics.
resultsTwelve eligible studies were included, with a total of 1217 patients. Overall, our findings demonstrated the efficacy of thiazide diuretics in preventing recurrent urolithiasis (RR = 0.55, 95% CI = 0.39 to 0.76). The Egger's test indicated that our analysis was free of publication bias (P = 0.092). In the dose-effect analysis, we observed that hydrochlorothiazide group using daily doses of 50 mg was statistically effective. Regarding the treatment duration, we found that treatment with all thiazide diuretics for ≤ 12 monthswas statistically insignificant, while treatment with all thiazide diuretics for 24 and 36 months was demonstrated to be effective. Treatment with hydrochlorothiazide for 36 months was also demonstrated to be effective.
conclusionsWe demonstrated the efficacy of thiazide diuretics in preventing recurrent urolithiasis. For the optimal dosage and treatment duration, we recommend a daily dose of 50 mg of hydrochlorothiazide for 36 months.
Indexed as
Identifiers
39960516What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.